72% reduction in hospitalisation from monoclonal antibodies, page-13

So they saved 9 (13 - 4) patients going to hospital out of 225. So what would those 9 patients have cost to treat in hospital on average? Some maybe mild and there for a few days and some may have gone onto to full ARDS though it's extremely hard to stratify as the drug may never had any effect on those with immune systems which go haywire. Thus they are only saving some lower cost mild cases from going to hospital.

But what we know with 100% certainty, for this drug to be effective, is it needs to be given to all patients who are newly diagnosed with C-19. Let's assume it is charged at $5K per patient as it is an expensive treatment, maybe more. Then the cost to stop those 9 additional patients going to hospital is 225 x $5K = $1.13M which means the saved costs for not hospitalizing those 9 patients would need to be 1.13M / 9 = $125K each to break even. Oh, the protection only lasts for a month, then what?

This treatment is too late. Either you get a life saving drug like Rem-L, a very specific targeted drug for certain high risk or costly patients or wait for a mass population and cheap vaccine. It can't be used as a mass population treatment which is how the trial is setup.